Legend Biotech Corporation LEGN

LEGN Company Overview

Legend Biotech Corporation is a clinical-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of cell therapies for oncology and other indications. The company operates primarily in the biotechnology and biopharmaceutical industries, with a strategic emphasis on chimeric antigen receptor T-cell (CAR-T) therapies. Its most significant commercial asset is ciltacabtagene autoleucel, marketed as CARVYKTI, a BCMA-targeted CAR-T therapy for multiple myeloma developed in collaboration with Johnson & Johnson Innovative Medicine through Janssen Biotech, Inc. The company generates revenue primarily through collaboration agreements, milestone payments, manufacturing activities, and product-related revenue associated with CARVYKTI commercialization.

Legend Biotech was founded in 2014 as a subsidiary of GenScript Biotech Corporation and later became independently listed on Nasdaq under the ticker LEGN in 2020. The company evolved from a broader life sciences and genomic engineering ecosystem into a focused cell therapy developer with integrated research, clinical development, and manufacturing capabilities. Its strategic positioning is supported by proprietary cell therapy technologies, vertically integrated manufacturing infrastructure, and a partnership model that leverages the global commercialization capabilities of Johnson & Johnson.